health
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Moody? Aggressive? You could have ‘irritable male syndrome’
New York Post
Ozempic and Wegovy linked to brain health risks from caloric cuts
Fox News
After 20 Miscarriages, Mom Celebrates Son’s First Birthday: ‘I Couldn’t Give Up’ (Exclusive)
Yahoo
5 Georgia siblings diagnosed with measles
WSB-TV
People Who Drink Their Own Pee Are Obsessed With AI, Using It to Reassure Themselves That It's a Miraculous Cure-All
Futurism